Suppr超能文献

一种用于测定人体组织样本中拓扑异构酶I mRNA水平的定量逆转录聚合酶链反应方法。

A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.

作者信息

Durand-Faucher Karine, Rabinovitch-Chable Hélène, Dzugan Hélène, Charret Stéphane, Aubry Karine, Genet Dominique, Léobon Sophie, Tubiana-Mathieu Nicole, Cook-Moreau Jeanne, Rigaud Michel, Sturtz Franck G

机构信息

Department of Biochemistry and Molecular Genetics, CHU Dupuytren, Limoges, France.

出版信息

Clin Chem Lab Med. 2005;43(7):707-14. doi: 10.1515/CCLM.2005.120.

Abstract

DNA topoisomerase I (Topo I) is involved in DNA replication, transcription, recombination and repair. Clinical interest has focused on Topo I as it is the molecular target of camptothecin (CPT), used in first and second lines of treatment for different cancer types. Furthermore, it is well demonstrated that the patients who best responded to CPT-based chemotherapy were generally those with the greatest tumoral Topo I expression and/or activity. We developed a sensitive, simple and reproducible method to measure Topo I mRNA expression in human cancer samples. Experiments were performed in two steps. First, we checked the accuracy of the reverse transcription-polymerase chain reaction (RT-PCR) method by testing intra- and interassay reproducibility of Topo I and G6PDH gene amplification in different cell types. We observed that crossing-points (Cps) were different, depending on the cell type, dilution or cDNA concentration, but that the intra- and interassay Cp standard deviation (SD) never exceeded 0.77% and 1.39% for Topo I amplification, or 1.63% and 2.9% for G6PDH amplification, respectively. Secondly, we used our method to measure Topo I mRNA levels in primary tumor samples obtained from 27 patients with advanced colorectal cancer and 10 patients with pharyngeal/laryngeal cancer. The accuracy of G6PDH as a housekeeping gene was tested by analyzing its correlation with the mRNA level of a second housekeeping gene, porphobilinogen deaminase (PBG-D) in the tumoral samples. We found that the normalized Topo I/G6PDH mRNA ratios were significantly correlated with that of Topo I/PBGD in colorectal tumors (r(2)=0.47, p=0.02) but not in pharyngeal/laryngeal tumors (r(2)=0.35, p=0.3). Neither ratio showed any significant association with clinicopathological parameters, such as gender, age, tumor size, or grade and lymph node status. We believe that RT-PCR is a reliable and highly reproducible technique. However, the choice of the reference gene is an important point and must be defined based on the samples studied.

摘要

DNA拓扑异构酶I(Topo I)参与DNA复制、转录、重组和修复过程。临床研究兴趣主要集中在Topo I上,因为它是喜树碱(CPT)的分子靶点,而CPT用于不同癌症类型的一线和二线治疗。此外,已有充分证据表明,对基于CPT的化疗反应最佳的患者通常是肿瘤组织中Topo I表达和/或活性最高的患者。我们开发了一种灵敏、简单且可重复的方法来检测人类癌症样本中Topo I mRNA的表达。实验分两步进行。首先,我们通过检测不同细胞类型中Topo I和G6PDH基因扩增的批内和批间重复性,来检验逆转录-聚合酶链反应(RT-PCR)方法的准确性。我们观察到,根据细胞类型、稀释度或cDNA浓度的不同,交叉点(Cps)也有所不同,但Topo I扩增的批内和批间Cp标准偏差(SD)分别从未超过0.77%和1.39%,G6PDH扩增的批内和批间Cp标准偏差分别从未超过1.63%和2.9%。其次,我们使用我们的方法检测了27例晚期结直肠癌患者和10例咽喉癌患者的原发性肿瘤样本中Topo I mRNA的水平。通过分析肿瘤样本中G6PDH作为管家基因与另一个管家基因胆色素原脱氨酶(PBG-D)mRNA水平的相关性,来检验G6PDH作为管家基因的准确性。我们发现,结直肠癌中标准化的Topo I/G6PDH mRNA比值与Topo I/PBGD比值显著相关(r(2)=0.47,p=0.02),而在咽喉癌中则无显著相关性(r(2)=0.35,p=0.3)。这两个比值均与临床病理参数,如性别、年龄、肿瘤大小、分级或淋巴结状态,无任何显著关联。我们认为RT-PCR是一种可靠且高度可重复的技术。然而,参考基因的选择是一个重要问题,必须根据所研究的样本进行确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验